The clinical application of gene-targeted drugs has transformed cancer therapy. The hallmark example of this strategy is use of the ABL kinase inhibitor imatinib for treatment of patients with chronic myeloid leukemia (CML). This remarkable clinical success has also stimulated an expansive search for personalized gene targets in all patients to facilitate broad application of targeted therapy for cancer. However, achievement of this objective will require simultaneous work towards several complementary goals. The first step towards broad application of gene-targeted therapy must entail a rapid means to identify target oncogenes in individual patients. Next, we must identify well-tolerated, gene-specific drugs that are collectively effective against a wide diversity of gene targets. Finally, we must develop protocols by which individual patients are matched with appropriate, gene-targeted drugs in a clinically relevant time frame. While these may seem like difficult tasks, we are fortunate to have a wide variety of new and rapidly evolving research tools at our disposal. These include next-generation sequencing of the genome and transcriptome, single nucleotide polymorphism (SNP)/copy number variations (CNV) and gene expression microarrays, and RNAi libraries for the application of functional screens. In this review we discuss the advantages and disadvantages of each of these techniques with the goal of demonstrating that no single technique will be sufficient as a standalone technology, but rather it will be the integration of all techniques that will enable broad application of gene-targeted cancer therapies.
Introduction
The Philadelphia chromosome was discovered in 1960 [Nowell and Hungerford, 1960] . However, it was not until the 1990s that an ABL kinase inhibitor was implemented for patient therapy, and a huge amount of necessary basic research was conducted during the intervening 3040 years to facilitate this clinical breakthrough [Druker et al. 2006 [Druker et al. , 1996 Daley et al. 1990; Heisterkamp et al. 1990; Kelliher et al. 1990; Ben-Neriah et al. 1986; Davis et al. 1985; Shtivelman et al. 1985; Collins et al. 1984; Gale and Canaani, 1984; Rowley, 1973] . Expansion of this paradigm of gene-targeted therapy to all cancer patients on a personalized level will clearly require faster identification and validation of gene targets. This difficult task becomes more complex when considering the wide variety of forms that can be adopted by oncogenic lesions as well as the numerous techniques available for target identification. Therefore, to consider the best approaches for personalized target identification in patients, it is useful to logically evaluate two criteria. First, cancer-causing genetic lesions must be subdivided into specific molecular categories (summarized in the next section and Figure 1 ). Second, it is important to carefully evaluate the analytical tools at our disposal and identify the relative strengths and weaknesses of each technique for gene target identification (summarized in the section on 'Techniques for the detection of oncogenic lesions'). Finally, the optimal integration of these functional genomics techniques will be considered to identify a platform by which these assays can work synergistically for the benefit of personalized cancer therapeutics (see the section on 'Assay integration for personalized cancer therapy').
Categories of genetic lesions
A wide variety of genetic lesions have been confirmed to contribute to disease pathogenesis in cancer patients. Although these molecular lesions can become extremely complex when considered at a nuanced level, for the purposes of simplicity these oncogenic lesions can be subdivided into four basic categories.
Gene fusions
Gene fusions can occur in several different ways. The quintessential example of a gene fusion in cancer is the Philadelphia chromosome [Nowell and Hungerford, 1960] , which is a balanced translocation between chromosomes 9 and 22 [Rowley, 1973] and leads to the gene fusion, BCR-ABL [Ben-Neriah et al. 1986; Davis et al. 1985; Shtivelman et al. 1985; Collins et al. 1984; Gale and Canaani, 1984] . Since that time, a large number of other gene fusions have been found to occur from chromosomal translocations of both the balanced and unbalanced variety. These gene fusions lead to dysregulation of a wide variety of gene types including kinases, phosphatases, transcription factors, and nonkinase receptors [Mitelman et al. 2007 ]. However, translocations are not the only molecular mechanism for generation of gene fusions. This type of oncogene can also result from microdeletions within single chromosomes as has recently been demonstrated in some patients with acute lymphoblastic leukemia exhibiting gene fusions of CRLF2 [Hertzberg et al. 2010; Yoda et al. 2010; Mullighan et al. 2009; Russell et al. 2009 ]. The mechanism for formation of gene fusions largely impacts on the capacity for various techniques to detect this form of genetic lesion, as discussed in the next section.
Point mutations
Single base substitutions that result in amino acid change within coding regions of genes are commonly found in cancer patients. Point mutations within H-RAS, K-RAS, and N-RAS in a wide variety of human cancers are classic examples of this type of lesion [Bos, 1989] . Point mutations can contribute to cancer pathogenesis by either increasing or decreasing the activity of the target gene to result in either oncogenes or tumor suppressors. Compared with gene fusions, point mutations are very subtle changes of genomic architecture and can, therefore, be difficult to identify in the absence of rationally guided search criteria. In addition, the identification of oncogenic point mutations is further complicated by the occurrence of a large number of 'passenger' mutations that are present in cancer genomes (and also in normal genomes), but that have no direct role in disease pathogenesis [George et al. 2008; Loriaux et al. 2008; Tomasson et al. 2008; Frohling et al. 2007 ]. As such, detection techniques for oncogenic point mutations must simultaneously satisfy two criteria: (1) they must be genome-wide to encompass all possible sites of genomic alterations; and (2) analysis must be guided by rational evidence indicating genes and pathways of interest so that bona fide pathogenic mutations can be distinguished from the vast number of passenger mutations present in every cell.
Gene overexpression
It is also possible for a wild-type gene that is expressed at an aberrantly high level to contribute to cancer pathogenesis. An early example of this phenomenon was the identification of HER-2 overexpression in certain cases of breast cancer [Slamon et al. 1987; Yokota et al. 1986 ]. Like gene fusions, overexpression of genes can occur by numerous distinct mechanisms such as point mutations within the promoter as is observed with the survivin gene [Xu et al. 2004] , amplification of a genomic locus such as HER2 or C-MYC [Augenlicht et al. 1997; Munzel et al. 1991; Mariani-Costantini et al. 1988; Slamon et al. 1987; Yokota et al. 1986; Little et al. 1983] , deletions or translocations that juxtapose the coding region of a gene in front of a different (more highly expressed) promoter [Yoda et al. 2010; Hertzberg et al. 2010; Mullighan et al. 2009; Russell et al. 2009; Marcu et al. 1992; Cole, 1986] , or aberrant methylation of a gene promoter. This last mechanism involving genomic methylation patterns is not dealt with in this review and has been extensively covered elsewhere [Herman and Baylin, 2003 ]. The exact mechanism causing a gene to become overexpressed has implications for the detection capacity of various analytical techniques, in a similar fashion as for gene fusions.
Missplicing
An emerging field in cancer genomics research involves mRNA splice variants that contribute to cancer pathogenesis. As analysis tools of the transcriptome have improved, it has become clear that most genes exhibit a much wider diversity of splice variants than was previously appreciated: many of which occur naturally and some of which appear to correlate with malignancy. It appears that these splice variants can arise in many ways. Some variants occur due to mutations within splice sites that prevent normal splicing while others occur due to the existence of cryptic splice sites that facilitate splicing at an abnormal location within the gene [Loo et al. 2003; Goodman et al. 2001 ]. However, it has also become apparent that mutation of the misspliced gene itself is not a prerequisite for missplicing to occur, but rather aberrant activity or expression of genes comprising the splicesome may result in the occurrence of this type of genetic lesion [Grosso et al. 2008] . In any of these cases, since the end result of misspliced genes can only be positively identified by analysis of transcriptional products, the analysis tools that can detect misspliced oncogenes are more limited than many of the previous lesion types.
Additional complexities
In addition to the variety of forms adopted by molecular lesions, gene target identification is further complicated by the complex protein interactions that result from cell signaling cascades. An entire signaling pathway may become dysregulated by a genetic lesion of just one gene within that pathway. Hence, a single oncogenic lesion can yield an entire signaling pathway of 'gene targets', even though most of these genes exhibit no molecular anomalies at the level of the genome or transcriptome. As such, genomic analyses of cancer cases exhibiting evidence of dysregulation of a particular gene must encompass the entire signaling cascade. Cumulatively, these complexities imply that integration of functional and genomic techniques will be far more efficient for gene target identification than any single standalone technology.
Techniques for the detection of oncogenic lesions
There are also a large number of analytical techniques that have been developed for detection of genetic lesions: far too many for complete coverage in this review. These technologies vary a great deal in terms of input requirements, cost, and theoretical capacity for detection of each of the above categories of oncogenic lesions. For simplicity, five basic assays will be considered.
RNAi functional screens
Since the discovery of RNAi, functional screens that take advantage of its specific gene-silencing capacity have emerged as enormously useful tools for target identification in cancer [Bric et al. 2009; Hu et al. 2009; Luo et al. 2009; Tyner et al. 2009 Tyner et al. , 2008 Ebert et al. 2008; Lam et al. 2008; Silva et al. 2008 Silva et al. , 2004 Zender et al. 2008; Ngo et al. 2006; Westbrook et al. 2005; Hannon and Rossi, 2004; Paddison et al. 2004 ]. These screens typically come in two distinct forms: segregated and pooled ( Figure 2 ). Segregated screens necessitate libraries of siRNA or shRNA where each target gene can be silenced individually. This is typically accomplished by creation of 96-or 384-well plates in which every well contains RNAi targeting a different, individual gene (Figure 2(a) ). The RNAi molecules are then introduced into malignant cells (via electroporation, lipososomal, or peptide delivery techniques for siRNA) and the cells remain compartmentalized throughout the duration of the screen. Endpoint analyses for segregated screens typically involve high-throughput readouts that can efficiently determine aggregate cell growth or cell death within each well. Any wells exhibiting an overall decrease in cell viability indicate that the target gene is acting in an oncogenic fashion, while wells exhibiting an enhancement of cell viability indicate tumor suppressor activity of the target gene.
Pooled screens take a different approach and are typically conducted using a retroviral delivery system where shRNAs are delivered in unison to a pool of cells (Figure 2(b) ). This pool of cells is then divided into two distinct components with one component being left untreated while the other is induced to express the stably integrated shRNAs. After a defined culture period, the two cell pools are compared using either microarray or next-generation sequencing technology to identify the frequency that each shRNA construct is represented within the uninduced and induced cells (each shRNA construct is tagged with unique sequences). Target genes of shRNA constructs that have been depleted from the induced compared with the uninduced cells are indicative of oncogenic activity, while target genes of enriched shRNAs are suggestive of tumor suppressors.
Both screening methods have strengths and weaknesses. Segregated screens allow for fast assay turnaround, because there is no need for the selection of cells or induction of RNAi expression. However, the size of segregated screen experiments also increases proportionately to the number of target genes included in the screen. As such, examination of large groups of target genes (or the whole genome) requires extensive experimental infrastructure. In contrast, pooled screens have elegantly solved this scalability problem by performing the gene silencing of all target genes in unison within a single cell culture vessel. As such, thousands of genes (or even the whole Therapeutic Advances in Hematology 2 (2) genome) can be examined without the need for complex machinery. However, this approach does necessitate the selection of cells for incorporation of shRNA vectors and also requires inducible expression of the shRNA molecule. As such, pooled screens require longer duration for completion of the experiment, which creates certain limitations as to the types of target cells that can be examined by this method. Despite the advantages and disadvantages of each type of RNAi screen, it is clear that both methods are highly capable of detecting the identity of unknown oncogenes in malignant cells. In fact, RNAi screens are one of the techniques that can be predicted to uncover the identity of all types of oncogenic lesions described in the previous section; however, several caveats must be considered. First, to achieve efficient silencing of a target gene, the specific portion of the gene with homology to the RNAi targeting sequence must be present. This is clearly not an issue when searching for genes with point mutations or overexpressed genes since the entire coding region of the gene is present in both cases. However, gene fusions and misspliced genes can be problematic, because entire portions of genes are absent from the transcriptome. As such, it is possible that RNAi screens will fail to detect these types of target lesions. For this reason, it is important to use libraries of siRNAs or shRNAs that contain multiple targeting sequences against several different portions of each target gene. A second important caveat is that many RNAi screens are conducted against only a subset of the genome (although whole genome screens have been accomplished [Hu et al. 2009; Luo et al. 2009; Brass et al. 2008] ). As such, these screens can fail to identify targets if the relevant siRNA or shRNA is not present on the RNAi library. In addition, many gene targets identified by RNAi screens may be secondary, interacting genes to the ultimate molecular lesion. Finally, a related caveat is that RNAi screens will only detect the identity of functionally important genes but will not identify the causative genomic lesion. As such, complete validation of the specific genetic lesions that underlie these functionally important targets in an efficient manner will require integration of RNAi screens with genome-wide molecular analysis techniques.
Whole genome sequencing
Whole genome sequencing (WGS) has become and will remain a vital technique for the discovery of the genetic basis of hematologic malignancies (and many other diseases). The first application of this technology in the field of hematology/ oncology was the sequencing of an entire acute myeloid leukemia (AML) genome [Ley et al. 2008 ]. This impressive study outlines a wellplanned, logical approach to WGS studies and clearly illustrates the need for careful data analysis due to the sheer magnitude of sequence variants that are observed in all individuals. This approach involves a series of analytical steps to sift through greater than 3.8 million single nucleotide variants observed in the tumor cell DNA of an AML patient to arrive at 10 genetic lesions suggested to play a role in the pathogenesis of this patient's leukemia (2 known lesions and 8 novel lesions). These steps include algorithms to predict high-quality variants (refined by experimental re-sequencing training sets), subtraction of sequence variants observed in WGS of matched skin DNA from the same patient, subtraction of polymorphisms observed in previously published genomes of individuals without cancer [Wheeler et al. 2008] , elimination of any variants not found in gene coding regions, and finally elimination of any variants not successfully verified as tumor-specific mutations by manual resequencing of both tumor and skin cell DNA.
Although this approach sets a fine standard for future WGS studies, it may be premature to conclude that all sequence variants deduced by such reasoning are truly contributing to disease pathogenesis. Certainly, the comparison of variants that are observed only in the tumor tissue and not in the patient-matched germline material would seem to indicate that these mutations are operationally important in leukemogenesis. However, this first AML genome actually exhibited 31,000 tumor-specific sequence variants that were not observed in the germline DNA, the single nucleotide polymorphism (SNP) database, or previous genomes of normal individuals. The reason that most of these variants were excluded from consideration is that they did not fall within gene coding regions and/or did not result in amino acid changes. Certainly not all of these mutations would have been reproducible upon manual resequencing since the success rate of mutation confirmation by manual sequencing appeared to be approximately 4% (8 confirmed out of 181 resequenced). Application of this 4% standard to all 31,000 tumor-specific variants would indicate the probable existence of approximately 1400 bona fide single-nucleotide sequence variants that were unique to the malignant cell DNA of this AML patient. While the existence of such a high number of tumor-specific genetic variants may initially seem surprising, it is important to recognize that the malignant DNA comes from a monoclonal population of cells while the normal DNA comes from a polyclonal cell population. Since every cell in our body accumulates 'passenger mutations' that are irrelevant to any disease-forming process, there will necessarily be a great deal of tumor-specific variants in any neoplastic clonal cell population that will not be found in patient-matched, normal polyclonal cells. Many of these variants may not be operationally important for disease pathogenesis. Hence, it may be premature to conclude that all nonsynonymous, tumor-specific sequence variants are functioning in a leukemogenic manner. In fact, this data suggests that there is a great deal of plasticity within the human genome: a fact that complicates WGS data analysis. One very interesting way to evaluate this hypothesized plasticity of the genome would be to clonally expand normal white blood cells and perform WGS on DNA from several normal, single-cell-derived populations. By comparing the sequence of each clonally expanded white blood cell population to DNA sequence of matched skin cells, one could estimate the rate at which individual normal cells accumulate random sequence variants. This estimate of the baseline number of passenger mutations present in any clonal cell population would be important for the interpretation of future WGS studies.
In summary, WGS is immensely powerful and represents a major step forward in the quest to decipher the specific genetic lesions that cause cancer in individual patients. However, used in isolation this technique also has the capacity for a high false-discovery rate. This should not diminish from the many strengths of this approach, but should be carefully considered in any wellbalanced research strategy.
RNA-Seq
RNA-Seq also makes use of next-generation sequencing technology and is, thus, subject to all of the caveats mentioned above for WGS. In contrast to WGS, however, this technique is directed towards analysis of the transcriptome rather than the genome. As such, this approach offers a number of strengths and weaknesses compared with WGS [Wang et al. 2009 ]. Since RNA-Seq is analyzing posttranscriptional material, it has the capacity for detection of all of the types of molecular lesions described in the previous section. However, one must also consider the relative ratios of transcripts within the transcriptome. Many genes that are known to exhibit oncogenic capacity when mutated, such as tyrosine kinases, exhibit low overall expression levels. This is not a problem when applying WGS, since each gene is represented twice (generally) in every genome so all genes are present at the same frequency. However, with RNA-Seq the depth of sequencing has dramatic implications for sequence coverage of low-expressing genes. As such, there is a far greater chance of inadequate sequence coverage for genes of interest using RNA-Seq compared with WGS. However, if adequate depth of sequencing can be achieved to deliver sequence coverage of the entire transcriptome, then RNA-Seq will theoretically be capable of detecting all classes of oncogenic lesions, including gene overexpression [Marioni et al. 2008; Mortazavi et al. 2008 ] and missplicing events [Sultan et al. 2008 ] that will likely be missed by approaches focused on the genome. Finally, although RNA-Seq will theoretically be capable of identifying each category of genetic lesion, this technique will often only reveal the identity of the candidate oncogene and may not reveal the actual genomic defect that causes the genetic anomaly to occur. This is especially true for gene fusions, gene overexpression, and missplicing. As such, coupling of RNA-Seq with techniques that directly analyze the genome will be important.
SNP/CNV microarrays
Microarray technology is similar to WGS in that it offers the capacity for whole genome analysis [Zhao et al. 2004; Pinkel et al. 1998 ]. However, it is different in that it relies on nucleic acid hybridization rather than sequencing technology. As such, one limitation of microarrays is that they confine analysis strictly to the probes that are present on the microarray. However, microarray technology has advanced to a point where coverage of the genome is very high on current platforms, resulting in capacity for high-resolution, whole genome analysis at significantly lower cost than current WGS and RNA-Seq experiments. Microarrays that can detect SNPs/copy number variations (CNVs) contain probes that collectively detect gain or loss of genomic copy number across the human genome. These regions of gain or loss could be indicative of genomic amplifications, deletions, or unbalanced translocations (balanced translocations are not detected due to neutral copy number of both chromosomes affected). As such, SNP/CNV arrays are clearly good tools for the detection of gene fusions (unless the gene fusions derive from balanced translocations). They may also have the capacity to predict gene overexpression events that derive from amplifications, deletions, and unbalanced translocations. In addition, SNP arrays can detect loci within cancer genomes where one allele has replaced its corresponding sister allele (uniparental disomy) [Gondek et al. 2008; Fitzgibbon et al. 2005; Raghavan et al. 2005; Zhao et al. 2004 ]. These genomic loci are likely to be hotspots for oncogenic mutations and, therefore, can guide follow-up sequence analysis to identify point mutations (or gene fusions). However, many point mutants exist without the occurrence of uniparental disomy and so will not be detected by SNP/CNV arrays. In addition, gene overexpression events that do not derive from amplifications, deletions, or unbalanced translocations will not be detected using SNP/CNV microarrays.
Exon/expression microarrays Gene expression microarrays use very similar technology as SNP/CNV arrays but analyze the cellular transcriptome rather than the genome [Alizadeh et al. 2000; Ross et al. 2000; DeRisi et al. 1996] . Gene expression arrays come in several varieties with the main distinctions being the placement of probes within different regions of gene transcripts. Standard gene expression microarrays typically place probes at only one or a few regions within transcripts to gather information only about the overall gene expression level and not about specific splice variants. In contrast, exon microarrays contain probes for every exon of a gene [Clark et al. 2007; Gardina et al. 2006 ]. As such, there are variable capabilities (and cost) of different formats of gene expression microarrays. Certainly, all gene expression microarrays are capable of detecting overexpression and probably represent the best tool for detection of this type of lesion. In addition, exon microarrays (but not standard gene expression microarrays) are capable of distinguishing between splice variants of genes. However, neither exon nor standard gene expression microarrays will detect point mutations. It is possible that gene fusions could be detected by either type of gene expression microarray; however, this would necessitate a change in expression level of one or both of the gene fusion partners to guide followup molecular analyses. As such, many gene fusions would be missed by all formats of gene expression microarrays.
Assay integration for personalized cancer therapy
Having now considered the various common types of oncogenic lesions as well as a variety of functional and genomic techniques that can be used for the identification of these lesions, it is useful to consider how best to proceed with personalized gene target identification in cancer. Clearly, one critical tool for this integrated strategy will be RNAi functional screening, because this technique can be conducted in a rapid manner and exhibits the capacity for the detection of gene targets arising from all oncogenic lesion types. In addition, RNAi screens can guide data analysis of high-throughput genomics techniques. However, RNAi functional screens do not reveal the actual site or type of genetic lesion, simply the identity of functionally important genes. As such, it will be critical to couple functional screens with genomic analysis tools that can cumulatively identify each type of oncogenic lesion. Broadly speaking, genomic techniques that directly analyze the genome, such as WGS and SNP/CNV microarrays will be most useful for the detection of gene fusions and point mutants. Techniques that analyze the transcriptome, such as RNA-Seq and gene expression microarrays are generally best suited for the evaluation of overexpression and missplicing of genes, although there are many exceptions and caveats to this rule ( Figure 2 ). Hence, a logical approach to personalized target identification would involve integration of functional screens with both a genome-oriented technique (WGS or SNP/CNV microarrays) and a transcriptomeoriented technique (RNA-Seq or gene expression microarrays). It seems clear that the techniques involving next-generation sequencing (WGS and RNA-Seq) will eventually be the format of choice for this integrated platform; however, cost must also be a consideration, and at the present time integration of both WGS and RNA-Seq in a high-throughput fashion would be cost-prohibitive for most investigators. In addition, neither WGS nor RNA-Seq are ideally suited to analyzing the gain or loss of genomic copy number, so SNP/CNV microarrays will still be useful for this purpose, even on samples for which both forms of next-generation sequencing have been performed.
Finally, there are a variety of highly useful techniques that have not been considered in this review but are certainly worth mention. In recent years, advances in techniques for analysis of the cellular and secreted proteomes have allowed for major contributions to our understanding of cancer pathogenesis [Walters et al. 2006a [Walters et al. , 2006b Wulfkuhle et al. 2003 ]. Indeed, many of the molecular changes involved in oncogenesis, such as phosphorylation of proteins, will not be detected by analyses that are restricted to the genome and transcriptome. In addition, the integration of flow cytometry with proteomics as well as the other techniques discussed in this review will continue to be a vital tool for cancer research as has recently been demonstrated by flow-cytometry-driven identification of novel mutations in the adaptor protein, LNK, in patients with myeloproliferative neoplasms [Oh et al. 2010; Irish et al. 2006 ]. Flow cytometry offers an enormously powerful tool to examine cancer cell populations at a nuanced level by analyzing cell subpopulations and even single cells rather than the oversimplified treatment of cancer as a homogenous block. Indeed, integration of functional screens, genomic techniques, and proteomics with flow-cytometry-driven single cell analysis will further propel investigations of cancer pathogenesis.
With the assistance of well-balanced research strategies incorporating most or all of the above techniques we can hope to accelerate the pace with which all forms of oncogenic lesions are identified. As these gene targets and associated genomic lesions are identified at an accelerated pace, it will also be important to meticulously catalogue these molecular lesions and match them with clinically viable, gene-targeted drugs. In this way, it will be possible to apply gene-targeted cancer therapies in a manner that is truly tailored to the needs of each patient.
Oncogenic lesions can be subdivided into four basic categories: gene fusions, point mutants, overexpressed genes, and misspliced genes. Functional profiling with RNAi screens as well as RNA-Seq both have the theoretical capacity to detect oncogenic lesions within each of these categories, however, RNAi screens will only reveal the identity of the candidate oncogene and RNA-Seq may be limited by the expression level of the oncogene. Techniques that analyze the cellular genome (WGS and SNP/CNV microarrays) are generally better suited for the detection of gene fusions and point mutants, while techniques focusing on the cellular transcriptome are more capable of identifying overexpressed or misspliced oncogenes.
RNAi screens are typically performed in one of two ways that differ based on whether RNAi is delivered individually or in unison to target cells. a. Segregated screens require libraries of siRNA or shRNA that are subdivided in 96-or 384-well plates. After gene silencing has occurred, target cells remain segregated in plates and endpoint analyses focus on the loss or gain of target cell viability to understand whether the silenced gene in each respective well was behaving in an oncogenic or tumor suppressor fashion. b. Pooled screens deliver lentiviral-packaged shRNA constructs into target cells in a single culture vessel. Target cells are then subdivided into two parts with one part left untreated while the second part has expression of shRNAs induced. Comparison of shRNA construct frequency in untreated versus shRNA-induced cells indicates oncogenic activity of depleted shRNA targets and tumors suppressor activity of enriched shRNA targets. mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 57: 17691775. 
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